
Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

June 14, 2019

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

Scrip Code: 524558

To
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001

Scrip Code: NEULANLAB
Series: EQ

Dear Sirs,

Sub: Corrigendum to the Notice of the 35th Annual General Meeting ("AGM")
Ref: Our letter dated June 10, 2019 enclosing Notice of the AGM

Please find enclosed a copy of the corrigendum to the Notice of the 35th Annual General Meeting of the Company scheduled to be held on July 5, 2019, published in the newspapers on June 14, 2019 and the Explanatory Statement to Item No.3 of the Notice of the AGM, referred in the corrigendum. These documents are available on the website of the Company along with the AGM Notice at www.neulandlabs.com.

Thanking You,

Yours faithfully,
For Neuland Laboratories Limited



Sarada Bhamidipati
Company Secretary

Encl : a/a

NEULAND LABORATORIES LIMITED

(CIN: L85195TG1984PLC004393)

Registered office: Sanali Info park, A Block, Ground Floor,
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034
Tel: +91-40-30211600; Website: www.neulandlabs.com



NOTICE OF THE ANNUAL GENERAL MEETING OF NEULAND LABORATORIES LIMITED

CORRIGENDUM

With reference to the Notice of the 35th Annual General Meeting ("AGM") dated May 16, 2019, dispatched to the shareholders of the Company on June 10, 2019, in respect of the AGM scheduled to be held on July 5, 2019, it is hereby requested to note the following:

1. The resolution set out at Item No.3 should be considered as Special Resolution, pursuant to Regulation 17(1A) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The explanatory statement regarding Item No.3 is available on the website of the Company at www.neulandlabs.com.
2. The following is included in the explanatory statement under Item No.4 on Auditor's appointment, after paragraph 2:

The proposed fee for the financial year ending March 31, 2020 is Rs.30,00,000/- (Rupees Thirty lakhs only), plus out of pocket expenses and taxes at the applicable rates, for services including statutory audit, limited reviews and tax audit. The Board, including relevant committee(s) thereof, shall be given the power to agree, alter and vary the terms and conditions of such appointment, remuneration etc. including by reason of necessity on account of conditions as may be stipulated by the Companies Act, 2013, in such manner and to such extent as may be mutually agreed with the auditors. In addition to the above and in accordance with the provisions of the Act, the Board / committees thereof, may approve other services, as deemed appropriate, and remuneration for such services as required by law or otherwise, subject to the provisions of section 144 of the Act.

This corrigendum should be read in conjunction with the Notice of the 35th Annual General Meeting.

For Neuland Laboratories Limited
Sd/-

Dr. Davuluri Rama Mohan Rao
Chairman & Managing Director
(DIN: 00107737)

Place: Hyderabad
Date : June 13, 2019

NEULAND LABORATORIES LIMITED

(CIN: L85195TG1984PLC004393)

Registered office: Sanali Info park, A Block, Ground Floor,
8-2-120/113, Road No.2, Banjara Hills, Hyderabad-500034
Tel: +91-40-30211600; Website: www.neulandlabs.com



NOTICE OF THE ANNUAL GENERAL MEETING OF NEULAND LABORATORIES LIMITED

CORRIGENDUM

With reference to the Notice of the 35th Annual General Meeting ("AGM") dated May 16, 2019, dispatched to the shareholders of the Company on June 10, 2019, in respect of the AGM scheduled to be held on July 5, 2019, it is hereby requested to note the following:

1. The resolution set out at Item No.3 should be considered as Special Resolution, pursuant to Regulation 17(1A) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The explanatory statement regarding Item No.3 is available on the website of the Company at www.neulandlabs.com.
2. The following is included in the explanatory statement under Item No.4 on Auditor's appointment, after paragraph 2:

The proposed fee for the financial year ending March 31, 2020 is Rs.30,00,000/- (Rupees Thirty lakhs only), plus out of pocket expenses and taxes at the applicable rates, for services including statutory audit, limited reviews and tax audit. The Board, including relevant committee(s) thereof, shall be given the power to agree, alter and vary the terms and conditions of such appointment, remuneration etc. including by reason of necessity on account of conditions as may be stipulated by the Companies Act, 2013, in such manner and to such extent as may be mutually agreed with the auditors. In addition to the above and in accordance with the provisions of the Act, the Board / committees thereof, may approve other services, as deemed appropriate, and remuneration for such services as required by law or otherwise, subject to the provisions of section 144 of the Act.

This corrigendum should be read in conjunction with the Notice of the 35th Annual General Meeting.

For Neuland Laboratories Limited
Sd/-

Dr. Davuluri Rama Mohan Rao
Chairman & Managing Director
(DIN: 00107737)

Place: Hyderabad
Date : June 13, 2019

Explanatory Statement in relation to Item No.3 is furnished and should also be taken as forming part of the Notice.

Item No 3: To appoint a Director in place of Dr. Christopher M Cimarusti (DIN: 02872948) who retires by rotation and, being eligible, seeks re-appointment.

Explanatory Statement

The members have at the Annual General Meeting of the Company held on December 28, 2017, approved the appointment of Dr Christopher M Cimarusti (DIN: 02872948), non-executive director, as a director liable to retire by rotation of the Company. In terms of Regulation 17(1A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, effective from April 1, 2019 consent of the Members by way of Special Resolution is required for appointment / continuation of a Non-Executive Director beyond the age of seventy-five years. The members have vide Postal Ballot Resolution dated March 23, 2019, approved the continuance of Dr.Cimarusti as a director, liable to retire by rotation.

Dr Christopher M. Cimarusti, aged 75 years, is a Non-Executive Director of our Company. He has completed his PhD in Organic Chemistry from Purdue University, USA and his Postdoctoral Research from Columbia University, USA. He has more than 50 years of experience in the field of drug discovery, development and manufacturing. He was awarded more than 60 patents and published more than 40 papers in referred journals. He provides consulting services to the pharmaceutical industry at Project Portfolio and Company strategy levels. Dr Cimarusti does not hold any equity shares in the Company. He is also a Director on the Board of Neuland Laboratories Inc.

Considering Dr.Cimarusti's expertise and experience in pharmaceutical industry, the Nomination & Remuneration Committee ('the Committee') and the Board of Directors of the Company ('the Board') are of the view that in order to take advantage of Dr. Cimarusti's advice and experience, it would be appropriate that he continues to serve on the Board.

Accordingly, the Board at the meeting held on May 16, 2019, on the recommendation of the Nomination & Remuneration Committee approved the appointment of Dr. Christopher M Cimarusti as Director of the Company, liable to retire by rotation.

Except Dr. Christopher M Cimarusti, none of the Directors, Key Managerial Personnel of the Company and their relatives is concerned or interested in the Resolution.

The Board recommends the special resolution set out at Item No. 3 of the Notice for approval by the members.